Skip to main content
. Author manuscript; available in PMC: 2014 Nov 7.
Published in final edited form as: JACC Heart Fail. 2014 Jun;2(3):260–268. doi: 10.1016/j.jchf.2013.12.004

Figure 3. Reclassification of 4 Year Predictive Probabilities of Pump Failure with Addition of Novel Biomarkers.

Figure 3

Graphic representation of reclassification across low and high risk of pump failure and change in predicted probabilities with addition of galectin-3 and ST2 to Clinical model + NT-proBNP in entire cohort (top panel), cases (middle panel), and controls (bottom panel). Overlapping shading in risk categories represents the number of patients reclassified with addition of galectin-3 (left column), ST2 (middle column), and ST2+galectin-3 (right column). For example, among all patients (top panel), the addition of galectin-3 (left most column) moved 23 low risk patients into the high risk category, and 25 high risk patients to the low risk category.